HIGHLIGHTS
- who: Lin Zhu from the (UNIVERSITY) have published the Article: Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report, in the Journal: (JOURNAL)
- what: This is the first report of an advanced and metastatic lung adenocarcinoma patient harbored EML4ALK and SETD2-ALK double-fusion variation and successively response to alectinib and immunotherapy combined with chemotherapy after alectinib resistant.
SUMMARY
At present, according to the National Comprehensive Cancer Network (NCCN) guidelines, the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.